Verastem said its Q2 2026 update showed commercial progress and further pipeline momentum in RAS/MAPK-driven oncology. The company is advancing Phase 2 programs

BWB News TV • 2026-08-06 20:11 UTC • By Billy Odell Tucker-Robinson

Verastem said its Q2 2026 update showed commercial progress and further pipeline momentum in RAS/MAPK-driven oncology. The company is advancing Phase 2 programs for VS-7375 in NSCLC and TARGET-D 203 in KRAS G12D metastatic colorectal cancer.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly